Please login to the form below

Not currently logged in
Email:
Password:

Lipoxen collaboration with Pharmasynthez

UK-based biopharma group, Lipoxen, has announced a collaboration deal with Russian, research-based pharma company, Pharmasynthez ZAO
The collaboration allows Pharmsynthez to apply Lipoxen's ImuXen and PolyXen proprietary technologies to a broad range of six drug and vaccine candidates.  

The aim is to create three enhanced vaccine candidates for secondary progressive multiple sclerosis (MS), HIV and non-Hodgkin's lymphoma and three pharmaceutical candidates for treatment of cystic fibrosis, acute myeloid leukaemia, non-Hodgkin's lymphoma and type 2 diabetes.

As a result of the agreement, Lipoxen will receive royalties of 10 per cent of all net sales from Pharmsynthez, should the products progress through clinical development and be approved for marketing in the Russian Federation. Any arising intellectual property will be jointly owned by the two parties, unless it relates solely to Lipoxen's platform technologies.

Pharmsynthez will optimise the candidates with guidance from Lipoxen and will complete testing to achieve clinical proof of principle by the end of 2010. Candidates that show promise will then progress to full-scale clinical development in Europe and the US.

Operating from the UK, Lipoxen develops high-value, differentiated pharmaceutical products in the areas of protein drugs, vaccines and anti-cancer drugs. The company was founded by Professor Gregory Gregoriadis, PhD, DSc, in 1997, as a spin-off from The School of Pharmacy at the University of London. In January 2006 Lipoxen became a London Stock Exchange AIM-listed company.

16th November 2009

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Porterhouse Medical Group

The Porterhouse Medical Group provides market research, insights, and scientific and medical communication services to the pharmaceutical industry across the...

Latest intelligence

Can we talk about the ego-bias and chemicals influencing your target audience’s behaviour?
Over the Summer, the Page & Page team became fascinated by two books on this very subject. Two books from one author, Dean Burnett, an eminent neuroscientist, lecturing at Cardiff...
Paris
Making Europe a leader in bioscience: boosting trust and opening minds
A vision of Paris as Europe’s leading hub for life sciences innovation...
Ali Frederic Ben-Amor
Tackling a formidable foe
Ali Frederic Ben-Amor tells how Merck is taking the fight to multiple sclerosis...

Infographics